Ask a urologist what surveillance for bladder cancer actually feels like, and you get a story about a camera. A thin scope, threaded through the urethra, checking a bladder that has an unfortunate habit of growing the same cancer again and again. It is effective, it is uncomfortable, and it happens over and over for years. Convergent Genomics, a genomic diagnostics company in South San Francisco, has spent a decade building the argument that most of that watching could be done with something a patient produces on their own: a cup of urine.
The company's test is called UroAmp. It takes the DNA shed into urine by the cells lining the urinary tract and sequences it - not with a small handful of markers, but across 60 high-impact urothelial cancer genes while also broadly measuring changes across the whole genome. Machine learning then turns that pile of mutations into something a clinician can act on: a positive or negative result, a predicted tumor grade, and a "Genomic Disease Burden" score that can be tracked over time, more like a running measurement than a one-off yes or no.
Convergent Genomics is, at its core, a laboratory. It was founded in 2015 by a team of cancer biologists, urologic oncologists, and data scientists, with roots at Oregon Health & Science University and a start through the Illumina Accelerator. It runs its own CLIA-certified, CAP-accredited clinical lab, and sells UroAmp as a service to the doctors who manage bladder and other urothelial cancers. That is the whole model: a specimen arrives, the lab reads its genome, and a report goes back to the physician.
01 / The ClaimReading cancer's mail before it is written
The headline result - the one that got the company written up across trade press in 2023 - came from banked urine samples collected long before anyone knew who would get sick. Running UroAmp on that old urine, researchers reported that the test could flag future bladder cancer up to roughly 12 years before a clinical diagnosis. In a group of patients who went on to develop the disease, it correctly pointed to future cancer in about 66% of cases, at a specificity of 94%. When the diagnosis arrived within five years of the sample, sensitivity rose to roughly 90%.
"Prediction" is a loaded word in cancer, and it is worth being careful with it. UroAmp is used as a detection and monitoring test, not a fortune teller for every patient. But the finding matters because it says something about where the signal lives: the genomic changes that eventually become a tumor are detectable in urine far earlier than a scope or a microscope can see them.
02 / The ProblemWhy bladder cancer is the perfect target
Bladder cancer is one of the most expensive cancers to manage, and the reason is recurrence. Non-muscle-invasive disease comes back frequently, which turns a single diagnosis into years of repeat cystoscopies and urine cytology. Cystoscopy is invasive; cytology, the standard urine test that looks at cells under a microscope, is specific but not very sensitive - especially for the low-grade tumors that are easy to miss and easy to let grow.
That is the gap Convergent is aiming at. In the company's reported comparisons, cytology caught about 12.5% of low-grade tumors; UroAmp caught 67%. For high-grade tumors, cytology caught roughly half, while UroAmp reached 100%. Another study made the point differently: UroAmp detected bladder cancer that both cystoscopy and cytology had missed. When the incumbent tools are that leaky, a molecular test does not have to be flawless to be useful.
Low- vs high-grade sensitivity
Reported tumor detection: UroAmp vs standard urine cytology.
03 / The ProductWhat UroAmp actually reads
UroAmp is not one test so much as a platform pointed at several jobs. In its detection role, it interrogates those 60 genes and the broader genome to decide whether urothelial cancer is present and to estimate its grade. In its UroAmp MRD role, it watches for minimal residual disease and recurrence after treatment, tracking a patient's tumor mutations over time - the kind of monitoring that turns a diagnostic into an ongoing relationship rather than a single sale. It also reports biomarkers that matter for treatment, including FGFR3 and MSI status, which are tied to FDA-approved therapies such as erdafitinib and pembrolizumab.
The quiet piece of engineering underneath all of this is logistics. UroAmp uses a patented Enhanced Preservation Media that keeps urine DNA stable for up to 14 days at room temperature. That sounds mundane until you realize it is what makes mail-in and remote collection possible: a patient can produce a sample away from a clinic and it will still be readable when it reaches South San Francisco. In diagnostics, the sample-handling problem is often the whole ballgame.
- Sequencing: next-generation DNA sequencing across 60 urothelial genes plus whole-genome breadth.
- Analysis: machine learning produces a Genomic Disease Burden score and grade prediction.
- Sample: urine, stabilized for 14 days at room temperature for remote collection.
- Biomarkers: FGFR3 and MSI status relevant to targeted and immunotherapy eligibility.
- Regulatory: laboratory-developed test; CLIA-certified and CAP-accredited; not FDA-cleared.
04 / The FieldA crowded cup
Convergent is not the only company trying to make the scope optional. Cxbladder from Pacific Edge, Nucleix's Bladder EpiCheck, and the older UroVysion FISH test all compete for the same surveillance decisions, and the broader liquid-biopsy world - Guardant Health, Natera and others - hovers nearby with blood-based approaches. UroAmp's differentiator is breadth: rather than reading a short list of markers or a set of methylation loci, it measures across the whole genome, which is what lets it produce a burden score that moves up and down over time.
The catch, and Convergent knows it, is that diagnostics companies rarely lose on science. They lose on evidence and habit. A systematic review of commercially available bladder assays excluded UroAmp for lacking studies in the specific settings - hematuria workup, routine surveillance - that clinicians care about most. The answer to that is not a louder press release; it is data. The company reports research across more than 30 sites worldwide, multiple peer-reviewed grants from the National Cancer Institute, and validation work published with OHSU collaborators on hundreds of samples. That is the long game a diagnostics startup has to play.
05 / The PeopleA repeat oncology founder's third act
The company is led by CEO Brian Slingerland, alongside founder Trevor Levin, who serves as president and chief scientific officer. Slingerland is not new to cancer companies: he co-founded Stemcentrx, the cancer-target company later acquired by AbbVie in a deal valued at up to $9.8 billion. That history is part of the read on Convergent - this is a founder who has built and exited in oncology before, now working on the detection end rather than the drug end.
On funding, Convergent has stayed relatively lean for a diagnostics company, with reported total capital in the low tens of millions and a backer list that includes the Illumina Accelerator, Civilization Ventures, HBM Genomics and Springboard Enterprises, plus federal research grants. The team is small - around 26 people - which fits a company that has chosen to spend on evidence and lab operations rather than a large commercial push.
06 / The TakeawayWhat a reader can steal
There are a few transferable lessons in Convergent's playbook, whether or not you care about urology. First: pick a market where the incumbent is genuinely weak, and let the comparison do your marketing - a test that beats cytology on low-grade tumors by 50-plus points barely needs adjectives. Second: solve the boring logistics problem, because a 14-day room-temperature sample is what turns a clever assay into a business. Third: in regulated categories, treat evidence as the product roadmap; the studies, the sites, and the grants are the moat.
Where would it not work? UroAmp's whole premise depends on cancer shedding enough DNA into urine to read - which is why urothelial cancers are a natural fit and why the same trick does not transplant cleanly to organs that do not conveniently drain into a collection cup. And a test that predicts disease years ahead raises a hard clinical question the company cannot answer alone: what should a doctor actually do with a positive result when there is nothing yet to treat? That is the frontier Convergent is now working to define, one study at a time.